Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management
|
Jun 2023
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes
|
Nov 2019
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Complement inhibition in medicine: Hematology and beyond; complement inhibition in hematology: PNH and beyond
|
May 2023
|
American Journal of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Myelodysplastic syndromes with ring sideroblasts (MDS-RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN-RS-T) - "2021 update on diagnosis, risk-stratification, and management"
|
Mar 2021
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Paroxysmal nocturnal hemoglobinuria: Where we stand
|
May 2023
|
American Journal of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Paroxysmal nocturnal hemoglobinuria: Where are we going
|
May 2023
|
American Journal of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Efficacy and safety of the C5 inhibitor crovalimab in complement inhibitor-naive patients with PNH (COMMODORE 3): A multicenter, Phase 3, single-arm study
|
Jul 2023
|
American Journal of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Clinical decision-making and treatment of myelodysplastic syndromes
|
Dec 2023
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Myelodysplastic Syndromes: 2021 update on Diagnosis, Risk-stratification and Management
|
Aug 2020
|
American Journal of Hematology
|
myelodysplastic syndromes (MDS)
|
Iron overload after complement inhibitor treatment of Paroxysmal Nocturnal Hemoglobinuria
|
Apr 2021
|
American Journal of Hematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|